Beyond the scale, researchers might begin to observe favorable changes in key metabolic markers, such as fasting glucose, insulin sensitivity, and lipid profiles
However, they should not be used with DPP-4 inhibitors (such as sitagliptin), and insulin or sulphonylurea doses may need adjustment to prevent hypoglycaemia
It is important to note that tirzepatide comes with a boxed warning for the risk of thyroid C-cell tumors, and may delay gastric emptying, which could affect the oral absorption of other medications
Australian Peptide supplies BPC-157 exclusively as a research material intended for laboratory investigation
Most researchers inject in the morning or evening, choosing a consistent time each week
[1] [2] Allergic reactions to tirzepatide can range from mild local injection site reactions to severe systemic hypersensitivity responses